Royalty Pharma (RPRX)

Total debt on the balance sheet as of September 2025 : HK$69.63 Billion

According to Royalty Pharma's latest financial reports the company's total debt is HK$69.63 Billion. A company’s total debt is the sum of all current and non-current debts.

Royalty Pharma - Total debt on balance sheet (from 2019 to 2025)

Total debt by year

Year	Total debt	Change
2024-12-31	HK$59.09 B	23.34%
2023-12-31	HK$47.91 B	-13.82%
2022-12-31	HK$55.60 B	0.49%
2021-12-31	HK$55.33 B	22.71%
2020-12-31	HK$45.09 B	-7.19%
2019-12-31	HK$48.58 B	-4.84%
2018-12-31	HK$51.05 B

Total debt for similar companies or competitors

Company	Total debt/th>	differencediff.	Country
ANI Pharmaceuticals ANIP	HK$4.82 B	-93.07%	🇺🇸 USA
Abbott Laboratories ABT	HK$100.74 B	44.66%	🇺🇸 USA
Eli Lilly LLY	HK$330.89 B	375.16%	🇺🇸 USA

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

Royalty Pharma (RPRX) - Total debt

Total debt on the balance sheet as of September 2025 : HK$69.63 Billion